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Abstract
Sexual behavior of HIV-positive youths, whether infected perinatally, through risky behavior or other ways, is not
substantially different from that of HIV-uninfected peers. Because of highly active antiretroviral therapy, increasing
number of children, infected perinatally, are surviving into adolescence and are becoming sexually active and need
reproductive health services. The objective of this article is to review the methods of contraception appropriate for
HIV-positive adolescents with a special focus on hormonal contraceptives. Delaying the start of sexual life and the
use of two methods thereafter, one of which is the male condom and the other a highly effective contraceptive
method such as hormonal contraception or an intrauterine device, is currently the most effective option for those
who desire simultaneous protection from both pregnancy and sexually transmitted diseases. Health care providers
should be aware of the possible pharmacokinetic interactions between hormonal contraception and antiretrovirals.
There is an urgent need for more information regarding metabolic outcomes of hormonal contraceptives,
especially the effect of injectable progestins on bone metabolism, in HIV-positive adolescent girls.
Introduction
Nong is just 15 years old. She was born in a remote part
of Thailand, infected with HIV since birth. Her father
died when she was one year old and her mother passed
away when she was six. Nong had a sister, but she also
died many years ago from AIDS. From an early age,
Nong was cared for by an old man, a distant relative
whom she calls “grandfather”.
Nong is smart and very sensitive. She likes going to
school, she is interested in drama and likes Thai boxing.
She does not like to talk to adults, and prefers chatting
with her teenage friends.
He was a boy from her school. They became friends.
When “it” happened she was scared and did not know
what to do. When Nong came to our clinic in January
2010 she was six months pregnant. She considered termi-
nation, but the pregnancy was too advanced. She cried
continuously and said that she wished she was back at
school. She did not want to stay in her own community
while pregnant. Nong moved to a temporary government
home for children and youths. She had good ARV adher-
ence and was determined for her baby not to be born with
HIV. In May she gave birth to a healthy little boy. A week
after delivery she gave her baby to an orphanage. In June,
she went back to school. On the last home visit she asked
about her baby and said that she was happy at school.
Background and objective
The objective of this article is to discuss methods of
contraception appropriate for HIV-positive adolescents
through a literature review, with special focus on hor-
monal contraception (HC).
According to the 2009 AIDS epidemic update, UNAIDS
[1], there are still close to 400 000 HIV infected babies
being born to HIV-positive mothers each year. Due to
highly active antiretroviral therapy (HAART), an increas-
ing number of children, infected perinatally, are surviving
into adolescence. Adolescents with perinatally acquired
H I Vi n f e c t i o n sa r eb e c o m i n gsexually active and are in
need of reproductive health services [2]. Furthermore,
approximately a quarter of all HIV-positive people,
infected in various ways, are below 24 years of age. Half of
this population is female.
The sexual behavior of HIV-positive youths is not sub-
stantially different from that of HIV-uninfected peers.
They are young and inexperienced but curious, and some-
times under the influence of substances [3]. A number of
studies looking into this topic have been conducted in the
United States. One of them from 2001 included almost
400 girls between 13 and 19 years of age from the Reach-
ing for Excellence in Adolescent Care and Health
(REACH) cohort [4]. There were about 100 pregnancies
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pregnancy incidence was detected between HIV infected
and uninfected participants. However, the authors noted
that among female adolescents who already had children
at entry, HIV infected females were significantly less likely
to become pregnant than HIV uninfected. The study
comes to a conclusion that there is a need to design better
contraceptive services and reproduction-related education
targeting high-risk youth.
Another study with 156 HIV-positive adolescents (13
to 21 years old), infected perinatally or through risky
behavior, also in the United States, showed that close to
2/3 of the participants were sexually experienced and
approximately half of them had engaged in risky behavior
since becoming aware of the diagnosis [5]. Forty-six of
the 99 perinatally infected participants reported to have
had sex. Nineteen out of 55 sexually active girls had been
pregnant. The authors rightly conclude that the risky sex-
ual behavior of perinatally infected adolescents is greater
than previously estimated and points to the need of
appropriate educational tools for early guidance in sexu-
ality and health of these young people.
Similar trends are noted in other parts of the world. A
study conducted in Bangkok, Thailand, that involved 70
HIV-positive young people between 16 and 25 years of
age showed similar results regarding risky sexual beha-
vior - almost half of the participants practised inconsis-
tent condom use [6].
In Brazil between 2000 and 2008, 4900 HIV infected
pregnant adolescents aged between 10 and 19 years
were reported [7]. The authors found that the timing of
first sexual intercourse and pregnancy among perinatally
infected girls is comparable to what is observed in the
general adolescent population. The Pan American
Health Organization reported that in Latin America,
50% of youths below 17 years of age are sexually active
and up to 25% of all babies are born to adolescents [8].
HAART gives children with HIV a chance to live, grow
up and enjoy life, including sex. It is the role of health
professionals to give young people the possibility to prac-
tise sex in a safe way. Appropriate sexual and contracep-
tive practice would help prevent the transmission of HIV
and other sexually transmitted diseases (STDs) as well as
unintended pregnancies [9]. It is increasingly important
that HIV-positive adolescent girls are offered reliable
family planning services.
What contraceptive methods are suitable for HIV-positive
adolescents?
A substantial choice of contraceptive methods exists -
abstinence, barrier methods, natural methods, HC,
intrauterine devices (IUD), sterilization and spermicides
[9,10]. It is unrealistic to expect all young people to
adhere to abstinence [8]. So far, a perfect method,
which provides effective contraception and STDs pre-
vention while having no side effects, and is completely
accepted by users in all situations, does not exist. This
is even more relevant in case of an STD such as HIV
infection when prevention of STD/HIV transmission is
restricted to using a barrier method that may not be
acceptable to many users. The protective benefit of male
condom is well documented [11]. But male condoms are
all too often not used as recommended, especially by
young people [12]. Therefore, in case of lack of absti-
nence, the use of two methods, one of which is the male
condom, is currently the most effective option for those
who desire simultaneous protection from both preg-
nancy and STDs [3,13,14]. Health workers who provide
family planning and STD/HIV prevention services
should continue to promote the dual protection method
even if uptake can be low especially among young users
[15].
A study published in March 2010 gave a population
estimate that if all women in the United States who use
one highly effective contraceptive method added a sec-
ond one, such as the condom, then approximately 80% of
unintended pregnancies and abortions among these
women could be prevented. This would result in an
annual reduction of 786,000 unintended pregnancies and
nearly 152,000 abortions [16].
When advising a young girl on available contraceptive
choices, we must take into consideration a number of
factors such as her young age and inexperience, a
dynamic pattern of life and sexual relationships, and of
course the concomitant condition of HIV infection and
ARV use. Advice on sexual risk and ways for delaying the
start of sexual life should begin as early as possible before
young people get used to risky behavior; ideally before
their first sexual intercourse. Today many programs on
sexual education to adolescents are developed and imple-
mented on different levels - parents, schools, community
- via professional educators or peers.
Though HIV-positive adolescents, and particularly
those on HAART, constitute a particular group, at pre-
sent there is not enough evidence related to the choice
of contraceptive method for this group. Sometimes we
have to give an empiric advice, based on information
about contraceptive use in adolescents in general, or
about contraceptives in HIV-positive women of any age.
Highly effective modern contraceptive methods
include HC, IUD and sterilization (male and female).
These methods do not protect from STD/HIV, but their
contraceptive effect is very high (< 0, 5 pregnancies/100
women/year in case of perfect use of the method).
Sterilization h a sm a n ya d v a n t a g e sa si tp r o v i d e s
excellent prevention of pregnancy and does not have the
side effects of other contraceptive methods and has no
pill burden. The disadvantage is that sterilization is a
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ethical questions, especially if it is conducted without
adequate counseling or if HIV-positive women are
forced to undergo the procedure as reported in some
countries [17]. In addition it requires an operative
procedure.
Although sterilization might be a choice for older
HIV-positive women who no longer desire to have chil-
dren, it is not a plausible option for adolescent girls. A
recent study in the general population showed that
women who undergo sterilization at a young age may
later regret this decision [18]. In this study women who
underwent sterilization at the age of 30 years or younger
were twice as likely as those over 30 to express regret.
They were also 3.5 to 18 times more likely to request
information about reversing the procedure and about 8
times more likely to undergo sterilization reversal or an
evaluation for in vitro fertilization.
The IUD, containing either copper or progestin, is the
most popular reversible long acting contraceptive
method used in the world. As compared to HC, the
IUD has the advantage of lacking pill burden, the need
for regular application and the adverse events associated
with hormonal components in the HC methods. The
progestin-releasing IUD has an advantage over the cop-
per IUD in reducing menstrual bleeding. A study con-
ducted in Zambia in 2007 reported that the IUD is a
safe and effective method of contraception in HIV-posi-
tive women [19]. The study randomly assigned 303
women to HC and 296 women to copper IUD. Women
who were assigned to HC were more likely to become
pregnant than those who were assigned to IUD (4.6 vs.
2.0/100 woman-years). Only one woman who was
assigned to the IUD group experienced pelvic inflamma-
tory disease (crude rate, 0.16/100 woman-years), and
there was no pelvic inflammatory disease among those
women who were assigned to HC.
Earlier reports showed higher incidence of adverse
events such as dysmenorrhea, expulsion, impaired
restoration of fertility with prolonged use of IUD in nul-
liparous and young women [20,21]. One study assessing
the use of Copper IUD (Copper T380) in 39 adolescent
mothers [22], found that six users had partial or com-
plete expulsion (15%), and 10 requested removals (26%)
within 24 months of placement. Furthermore, four users
(10%) became pregnant - three had an IUD in place at
time of conception, while one became pregnant due to
unrecognized device expulsion. The authors noted that
even though many adolescent mothers discontinued
IUD use within two years of placement, the numbers of
patients were too small to provide stable estimates of
contraceptive effectiveness. The study supports the need
for further studies of IUD in adolescents.
On the other hand more recent studies find that IUD is
a safe and effective long-term contraceptive method for
t h ea b o v ed i s c u s s e dp o p u l a t i on [23]. The article con-
cludes that because adolescents contribute disproportio-
nately to the epidemic of unintended pregnancy, IUDs
should be considered as a first-line contraceptive choice
regardless of parity. The World Health Organization
(WHO) puts the IUD for nulliparous and women below
20 years of age in category 2 - the advantage of using the
method generally outweighs the theoretical or proven
risk [24].
HC for HIV-positive adolescents - questions to be
answered
HC is a highly effective modern method of contracep-
t i o n .T h e r ea r et w om a i nt y p e so fH C .T h ef i r s to n ei s
the combined estrogen and progestin type which
includes the combined oral contraceptive pill (COC),
the skin patch or the vaginal ring. The second one is
the progestin-only type which could be delivered as a
pill, a depot injection or an implant.
Despite the topic of HC being discussed in recent
years in several excellent review articles [25-28], there
are few original studies in this field. When considering
HC for HIV-positive adolescents, one should think
about the following issues: HIV disease progression,
genital tract HIV shedding and infectivity, pharmacoki-
netic (PK) interactions between hormones and ARVs
and last, but not least - metabolic outcomes.
HIV Disease progression
Data on the effect of HC on HIV disease progression is
still inconclusive. Sex steroid hormones influence the
immune system; progesterone can have a suppressive
effect whereas estrogens can have the reverse [29,30].
The exact mechanisms are not clearly understood. In
addition to influence on the immune system, estrogens
and progesterone have an effect on the structure of the
vaginal epithelial wall and the vaginal microorganisms.
Epidemiologic studies in humans [31,32] and challenge
studies in ovariectomized macaques [33,34] suggest that
progesterone-based contraceptives increase the trans-
mission risk of HIV-1 infection in humans and of simian
immunodeficiency virus (SIV) infection in macaques due
to increase viral shedding in the genital tract, while
estrogens made macaques resistant to SIV, mainly due
thickening of the vaginal epithelium.
Baeten et al. demonstrated in the Mombasa cohort
that the use of depot medroxyprogesteron acetate
(DMPA) at the time of HIV infection was associated
w i t hah i g h e rp l a s m aH I V - 1v i r a ll o a ds e tp o i n t ,w h i c h
predicted faster progression of the HIV-1 disease [31].
They also showed that women using HC, COC or
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acquire multiple HIV viral genotypes, which in turn was
associated with higher HIV plasma viral load set point
and faster CD4 T cell decline. A study conducted in
Zambia suggests that HC might enhance disease pro-
gression if administered in HIV-positive women prior to
ARV [32]. The researchers randomized 599 HIV-
infected women to either a non-hormonal contraceptive
method, such as an IUD, or a HC, such as COC pill or
DMPA. Disease progression was defined either as death
or becoming eligible for ARV. They found that COC or
DMPA use was associated with HIV disease progression
among women not yet on ARV.
On the other hand, data from a multi-country cohort
analysis involving 4,000 women, published at the end of
2009 by the same group of researchers, did not find an
effect of exogenously administered progesterone on
HIV-1 acquisition and disease progression [35].
There are several other studies published in recent years
which confirm the same observation. A study from Uganda
with 625 women finds that HC is not associated with pro-
gression to death and is actually associated with reduced
p r o g r e s s i o nt oA I D S[ 3 6 ] .I n HIV-infected postpartum
Kenyan women, the results were similar with no significant
immediate or longer-term effects of the use of COC or
DMPA on HIV-1 plasma viral load and CD4 T-cell counts
[37]. The role of HC in the effectiveness of HAART was
examined among participants in the Women’sI n t e r a g e n c y
HIV Study who were followed from HAART initiation
[38]. The authors did not find any substantial evidence that
u s eo fH Cs t r o n g l ya f f e c t e dr e s p o n s e st oH A A R T .
Scientific evidence is currently not conclusive about
HIV progression and contraceptive use. HC use in
women on HAART does not show progression and there
are not enough studies in HIV infected adolescents in
this regard.
PK interactions between hormones and ARVs
Another important consideration involving HC in HIV
positive women is the PK interaction between hormones
and ARV drugs. There are several review articles
[26-28] on the topic and only a limited number of stu-
dies with mostly small sample size and short duration of
exposure to both hormones and ARVs. Most of the stu-
dies are based on the assumption that as sex steroid
hormones are predominantly metabolized via the cyto-
chrome P450 system. Any medication which affects this
pathway, such as some ARVs would change the PK of
estrogens and progestins. The decrease in hormone
levels could potentially decrease the contraceptive effect
whereas the increase in hormone levels could potentially
increase hormone-related side effects (e.g. thromboem-
bolism). However, the area under the curve (AUC) and
the maximal concentration (Cmax) of any drug are
dependent on multiple factors such as age, body weight,
hormonal cycles of exposure to the drug (HC, ARVs),
the specific drug molecule and its dosage. Furthermore,
in adolescents, activity of drug metabolizing enzymes is
influenced by the physical and sexual development, with
greatest variability in puberty [39]. However, informa-
tion in this field is limited and there is need for further
studies. Last, but not least, PK differences of sex steroid
hormones may not be as important as the direct indica-
tors of pregnancy risk such as ovulation during the oral
contraceptive cycle [40-42].
Nevertheless, we will briefly present the studies con-
ducted in this field. We will divide the PK studies into
two groups depending on the HC: progestin-only HC
(DMPA) and combined, estrogen and progestin hormo-
nal contraceptive.
PK studies of DMPA and ARVs
There are two studies assessing the interaction between
DMPA and ARVs (Table 1). Cohn, Watts et al. [43,44]
enrolled 70 HIV-positive women, 22 to 46 years of age,
in four groups depending on their ARV regime - nucleo-
side reverse transcriptase inhibitors (NRTI) only, two
NRTIs and one protease inhibitor (PI), nelfinavir (NFV),
two NRTIs and one non-nucleoside reverse transcriptase
inhibitor (NNRTI), either efavirenz (EFV) or nevirapine
(NVP). The NRTI-only group served as a control group,
as NRTIs have a different metabolic pathway and are not
expected to have an impact on PKs of sex hormones.
DMPA was administered once during the study in a stan-
dard dose of 150 mg by intramuscular injection. Blood
levels of DMPA, progesterone and respectively of ARVs,
NFV, NVP and EFV were measured. There were no sig-
nificant changes in medroxyprogesterone acetate levels in
any of the three groups (NFV, EFV or NVP) compared to
the control group. Minor changes in NFV and NVP drug
exposure were seen after DMPA, but were not consid-
ered clinically significant. Suppression of ovulation,
assessed by progesterone levels, was maintained. The
study concludes that DMPA can be used safely by HIV-
positive women on the ARVs studied.
In 2007 Nanda et al. made similar findings in a group
of women on two NRTIs and EFV [45]. A single standard
dose of DMPA was administered. PK of DMPA was simi-
lar compared to a group of HIV-positive women without
ARV. The authors conclude that the DMPA levels are
not affected by EFV.
PK studies of COC, ethinyl estradiol (EE)/progestin, and
ARVs (NNRTIs, Nucleotide reverse transcriptase inhibitors
(NtRTI) and PIs)
NRTIs include molecules such as zidovudine (AZT), sta-
vudine (d4T), lamivudine (3TC), didanosine (ddI), aba-
cavir (ABC) and others. NRTIs are not metabolized via
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PK studies assessing the interaction between DMPA and ARVs
Author n ARV Hormones Outcome
1. Cohn, Watts et
al, 2006 (43,
44),
pharma
sponsored
partly
70 HIV+,
22-46 y
NFV (n = 21)
EFV (n = 17)
NVP (n = 16)
NRTI only (n = 16)
DMPA, single dose ↓ NFV
↑ NVP
EFV - no significant change
DMPA - no significant change
Progesterone < 1.6 ng/ml, no ovulation
Conclusion: DMPA is an effective contraceptive
method for HIV+ women on ARVs in the study
2. Nanda et al.,
2007 (45)
30 HIV+,
19-40 y
AZT+3TC+EFV DMPA, single dose ARV levels - not done
DMPA - no significant change
Progesterone - only in one woman (control group)
> 5 ng/ml, might indicate ovulation
Conclusion: DMPA is an effective contraceptive
method for HIV+ women on triple ARV regime in
the study
PK studies assessing the interaction between EE, progestins and NNRTIs and NtNRTI
1. Mildvan et al.,
2002 (46),
pharma
sponsored
10 HIV+,
26-47 y
NVP 200 mg BID 0.035 mg EE/1.0 mg NET, single
dose
↓ 29% AUC of EE
↓ 18% AUC of NET
NVP - no significant change
Conclusion: COC should not be primary method for
contraception in HIV+ women on NVP
2. Joshi et al.,
1998 (47),
pharma
sponsored
13 HIV- EFV 400 mg OD, 7
days
0.05 mg EE, single dose ↑ 37% AUC of EE
EFV - no significant change
Conclusion: no decrease in EE levels when co-
administered with EFV
3. Sevinsky et al.,
2008 (48),
pharma
sponsored
28 HIV-,
18-42 y
EFV 600 mg OD,
14 days
EE/NGM, 3 cycles EE - no significant change
↓ 64% AUC of NGMN
↓ 83% AUC of LNG
EFV - no significant change
Progesterone < 1.25 ng/ml
Conclusion: need of reliable barrier contraception
when taking COC with EFV
4. Scholler-Guyera
et al., 2009 (49),
pharma
sponsored
30 HIV-, 18-45 y ETR 200 mg BID 0.035 mg EE/1.0 mg NET, 3
cycles
↑ 22% AUC of EE
↓ 5% AUC of NET
↑ ETR
Conclusion: no compromise in contraceptive effect
5. Kearney et al.,
2009 (50),
pharma
sponsored
20 HIV-,
19-45 y
TDF 300 mg OD EE/NGM, 3 cycles EE - no significant change
NGM - no significant change
TDF - no significant change
Conclusion: TDF does not alter PK of EE and NGM
PK studies assessing the interaction between EE, progestins and PIs
1. Ouellet et al.,
1998(51),
pharma
sponsored
23 HIV-, 18-45 y Ritonavir
500 mg BID
0.05 mg EE, single dose ↓41% AUC of EE
Conclusion: use an alternative contraceptive method
when ritonavir is administered
2. Frohlich et al.,
2004(54),
pharma
sponsored
partly
8 HIV-,
23.8 y
Saquinavir single
dose
0.03 mg EE
0.075 mg gestoden
SQV - no significant change
Conclusion: COC does not alter single dose
saquinavir
3. Tacket et al.,
2003 (55),
pharma
sponsored
22 HIV- ATZ 400 mg 0.035 mg EE/1.0 mg NET ↑ 48% AUC of EE
↑110% AUC of NET
Conclusion: no compromise in contraceptive effect,
no dose adjustment needed
4. Sekar et al.,
2008 (52),
pharma
sponsored
19 HIV- DRV/r 600 mg/100
mg BID
0.035 mg EE/1.0 mg NET, 2
cycles
↓44% AUC of EE
↓14% AUC of NET
Conclusion: use an alternative method
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expected to influence sex steroid hormone levels. The
same is valid for the NtRTI, among which the drug
tenofovir (TDF). At present, NRTIs are the backbone of
standard ARV regimes.
The NNRTIs, such as NVP and EFV are part of most
first line therapies. Etravirine (ETR) is a second genera-
tion NNRTI that has higher threshold for resistance
compared to EFV and NVP. They are metabolized pri-
marily via the cytochrome P450 path; therefore, interac-
tions with sex steroid hormones are expected in both
directions. The studies evaluating the interaction
between EE, progestin and NNRTI or NtRTI are listed
in Table 1.
The interaction between NVP and EE with norethin-
drone (NET) was studied by Mildvan et al. in 10 HIV-
positive women [46]. The selected participants had to be
o nas t a b l et r i p l eA R Vr e g i m ef o ra tl e a s to n em o n t h
prior to enrollment in the study. The ARV regime did
not have NVP or ritonavir( R T V ) .O nd a y0as i n g l e
dose of 0.035 mg EE/1.0 mg NET was given, followed
by measurement of EE and NET levels. NVP was added
to the therapy in an initial dose of 200 mg once daily
for 15 days, followed by 200 mg twice daily for addi-
tional 15 days. On day 30 another single dose of 0.035
mg EE/1.0 mg NET was given and blood levels of EE,
NET and NVP were measured. The authors found a
29% reduction of EE and an 18% reduction of NET
levels in AUC. NVP levels were not changed signifi-
cantly compared to historical data. They concluded that
COC should not be the primary method of birth control
in women of child-bearing potential who are treated
with NVP.
There are two small studies assessing the interaction
between EFV and EE or EE/NGM (norgestimate) con-
taining COC, and the active metabolites of NGM - nor-
elgestromin (NGMN) and levonorgestrel (LNG) [47,48].
They were conducted in a small sample of HIV-negative
women, the first one with 400 mg EFV for one week
and 0.050 mg EE only, and the second one with 600 mg
EFV for two weeks prior to EE/NGM administration.
The first study found increase in EE levels and no signif-
icant changes in EFV levels [47]. The other also found
no change in EFV levels, as well as no change in EE
levels [48]. The progestin levels, NGMN and LNG, were
significantly reduced; though participants most probably
did not have ovulation (serum progesterone remained
low). In conclusion there is a need to use reliable barrier
contraception when taking COC with EFV.
The effect of ETR on PK of 0.035 mg EE/1.0 mg NET
was assessed in 30 HIV-negative women [49]. The
authors concluded that the changes in EE and NET
were not clinically relevant, and no loss in contraceptive
efficacy was expected when hormones were co-adminis-
tered with ETR.
The potential interaction between EE/NGM was
assessed with TDF [50]. PK parameters for NGM and
EE were unaltered by co-administration of TDF, as were
the levels of TDF.
There are published studies on PK interaction
between several PIs and COCs (Table 1). In 1998 Ouel-
let et al. [51] administered RTV, as a single PI in healthy
volunteers, in gradually increasing doses for 30 days
from 300 mg to 500 mg twice daily. At the same time
on day 1 and day 29, 0.05 mg of EE was administered.
The EE blood levels measured on day 29 were reduced
by approximately 40% in comparison to day 1. The
authors consider the reduction significant and recom-
mend the use of an alternative contraceptive method
w h e nR T Vi su s e d .I nc l i n i c a lp r a c t i c eR T Vi sp r i m a r i l y
used in lower doses, usually 100 mg twice daily, as a
booster to PIs. We found two studies assessing PK inter-
action between EE and RTV boosted PIs [52,53]. Both
studies found reduction in the EE levels when co-admi-
nistered with RTV boosted PI, which the authors con-
sidered significant. We present details of these studies
further in the article.
Frohlich et al. [54] studied the effect of 0.03 mg EE/
0.075 mg gestodene on saquinavir (SQV) in healthy
volunteers based on the premise that women had more
adverse drug reactions to ARVs than men. The results
showed no effect of OC on SQV PK.
Table 1 PK studies assessing the interaction between HC and ARVs (Continued)
5. Vogler et al.,
2010 (53)
8 HIV+ with LPV/r,
24 HIV+ w/o LPV/
r
LPV/r
400 mg/100 mg
0.035 mg EE/1.0 mg NET, single
dose EE/NGMN skin patch for 3
w
↓45% AUC of patch EE
↑83% AUC of patch NGNM
↓55% AUC of pill EE
↓19% AUC of LPV with patch
↓23% AUC of RTV with patch
Progesterone < 2.88 ng/ml, no ovulation
Conclusion: PK of EE/NGMN significantly altered, but
clinical effect probably not affected
NFV = nelfinavir, EFV = efavirenz, NVP = nevirapine, NRTI = nucleoside reverse transcriptase inhibitor, AZT = zidovudine, 3TC = lamivudine, DMPA = depot
medroxyprogesterone acetate, EE = ethinyl estradiol, NET = norethindrone, NGM = norgestimate, NGMN = norelgestromin, LNG = levonorgestrel, ETR =
etravirine, TDF = tenofovir disoproxil fumarate, RTV = ritonavir, ATZ = atazanavir, SQV = saquinavir, DRV/r = ritonavir boosted darunavir, LPV/r = ritonavir boosted
lopinavir, COC = combined oral contraceptive, PK = pharmacokinetic, AUC = area under the curve, ↑ = increase, ↓decrease, OD = once daily, BID = twice daily,
pharma sponsored = the study is financed by a pharmaceutical company (manufacturer of drugs under study)
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conducted by a manufacturer with atazanavir (ATV) [55]
and low dose RTV-boosted darunavir (DRV/r) [52]. The
administration of 400 mg of ATV without boosted RTV,
with 0.035 mg EE/1.0 mg NET led to a 48% and 110%
increase of AUC of EE and NET, respectively. No dose
adjustment of COC was recommended. In the second
study of DRV/r, there was a decrease of 44% in EE AUC
and 14% in NET AUC, respectively. The PK interaction
observed here is considered to be clinically significant
and the study recommends the use of an alternative or
additional contraceptive method.
The interaction between Maraviroc, a CCR5 receptor
agonist and 0.03 mg EE/0.15 mg LNG in 14 HIV-negative
women was assessed [56]. The concentrations of EE and
LNG remained similar with and without Maraviroc.
There are several other studies that assessed the interac-
tions between indinavir (IDV), amprenavir (APV), nelfi-
navir (NFV), and COC in HIV-negative women [57-59].
After co-administration of 800 mg IDV three times daily
with 0.035 mg EE/1.0 mg NET, slight increase of AUC of
EE (22%) and NET (26%) was observed. PK assessment of
APV with EE/NET showed similar results - no significant
change in EE levels and slight increase in NET AUC of
18%. The contraceptive effect of COC is not compro-
mised when administered with IDV and APV. NFV
(750 mg) administered three times daily with 0.035 mg
EE/1.0 mg NET led to 47% decrease of AUC of EE and
18% of NET, which might require the use of an addi-
tional or alternative method of contraception.
One interesting study by Vogler et al. reported the inter-
action between RTV-boosted lopinavir (LPV/r) and EE/
NGMN delivered through a skin patch in HIV-positive
women [53]. There were eight participants with HC and
triple ARV regime including LPV/r 400 mg/100 mg twice
daily and two NRTIs, and a control group without ARV,
or NRTI only regime, of 24 participants. After a single
dose of COC (0.035 mg EE/1.0 mg NET), EE and NET
levels were measured. Two days later a patch was adminis-
tered for three weeks, changing every week. EE and
NGMN levels were measured multiple times during the
study period. The AUC of EE was decreased in the LPV/r
group compared to the control group for both the COC
(55%) and the patch (45%), while the AUC of NGMN was
increased by 83% in the LPV/r group in comparison to the
control group. The AUC of LPV was decreased by 19%
and of RTV by 24%, respectively. Serum progesterone
levels remained low in all participants, showing no signs of
ovulation. The authors concluded that although PKs of
contraceptive EE and NGMN were significantly altered
with LPV/r, the contraceptive efficacy of the patch was
likely maintained.
All existing data point to the conclusion that despite a
decrease or increase in the blood levels of sex steroid
hormones, the efficacy regarding their contraceptive
effect is most probably not compromised, as all major
studies measured also levels of progesterone at least once
[43-45,48,53]. Serum progesterone levels remained
always below 5 ng/ml, values consistent with anovulation
[60]. Only in one woman serum progesterone was above
5 ng/ml [45]. She was from the control group, without
ARV, and the HC under study was DMPA, with which
suppression of ovulation is not the only way of ensuring
contraceptive effect. Despite this outcome, in all major
guidelines [10], the recommendation is to use an alterna-
tive or additional method of contraception when using
combined HC with NNRTIs (NVP or EFV), or RTV-
boosted PIs. All of these studies, with the exception of
two [45,53], were conducted by the research department
of the pharmaceutical companies [46-52,55-59], or partly
co-funded by the pharmaceutical companies [43,44,54].
More studies with higher numbers of participants
in “real-life situations” are needed to confirm this
conclusion.
We did not find studies evaluating to what extent this
increase or decrease in blood levels of EE and progestin
affects the non-contraceptive effects of HC. Some of
these effects, such as improvement of acne and reduction
of menstrual pain could be very beneficial, especially
among adolescent girls [61]. Others, such as deep venous
thrombosis, might be fatal and there is an urgent need
for more information in this field.
Metabolic and bone outcomes of hormonal
contraceptives in female adolescents and adults
Because of the potential effects of HIV infection, ARV
and hormones themselves on body metabolism, we might
expect more changes in plasma lipids and glucose toler-
ance in HIV-positive women using HC, especially with
progestin-only HC. The issue has been studied by
Womack et al [62] who enrolled HIV-infected and unin-
f e c t e dw o m e ni nt h eW o m e n ’s Interagency HIV Study
(WIHS), an ongoing multicenter longitudinal cohort
study of the progression of HIV infection in women. The
authors found that progestin-only and combined HC
impact metabolic outcomes differently. Progestin-only
HC was associated with lower high density lipoprotein
(HDL) and greater insulin resistance in HIV-infected and
uninfected women. On the other hand, combined HC
was associated with higher HDL in HIV-infected and
uninfected women. This information is of particular
interest as progestin-only HC is gaining popularity
among HIV-positive women due to the clearer pattern of
PK interaction with ARVs.
The impact of HC on bone density in HIV-positive
adolescents is unfortunately much less studied. HC,
especially DMPA and to a lesser extent low dose COC,
has been associated with loss of bone mineral density
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status.
In 2004, the US Food and Drugs Administration (FDA)
added a black box warning to the package insert of
DMPA [64], stating that women who use DMPA contra-
ceptive injection may have significant BMD loss and that
it is unknown if the use of the DMPA during adolescence
or early adulthood, a critical period of bone accretion,
will reduce peak bone mass and increase the risk of
osteoporotic fracture later in life. They recommend not
using this method for more than two years, because of a
possible decrease in the amount of calcium in the bones,
especially in case of an additional factor such as smoking
or drinking which carries a risk of osteoporosis.
This FDA black box provoked much discussion and
many studies were conducted in this field. A multicentre
study in the USA with 98 long term DMPA users (up to
240 weeks) between the ages of 12 to 18 years concluded
that BMD loss in female adolescents receiving DMPA is
substantially or fully reversible in most girls following dis-
continuation of DMPA, with faster recovery at the spine
level than at the hip [65].
A study conducted in Thailand [66] on the long-term
use of DMPA on BMD found that long-term use of
DMPA had a negative impact on lumbar spine BMD.
We did not identify similar studies conducted in HIV-
infected adolescents or women. There is an urgent need to
study the topic in this group as DMPA is considered safe
to use with HIV infection due to its favorable interaction
with ARVs [43-45]. On the other hand, low BMD is preva-
lent in HIV infected women [67,68]. The start of HAART
leads to a 2% to 6% decrease in BMD over the first 2
years, due to multiple factors, among which are HIV infec-
tion, ARVs, traditional osteoporosis risk factors, and
increased fracture rates in the HIV-infected population.
Mora et al. studied the growth of skeletons in children
and adolescents, and found a typically high bone cell activ-
ity [69]. The study found that HAART-treated children
had higher levels of bone formation and bone resorption
compared with healthy controls, with an association
between ARV and enhancement of bone metabolic rate.
An increased rate of bone turnover causes BMD decrease.
The authors also found a relation between the severity of
osteopenia and lipodystrophy.
After reviewing available data on HC in HIV-infected
women and finding practically no information on HIV-
infected adolescent girls, we consider that the PK inter-
action between HC and ARVs is perhaps of higher
importance in its impact on metabolism and bone than
on contraception in this group.
Emergency contraception (EC)
At the end of this review article we assess possible
options for EC in HIV-positive adolescents. This is not
a form of contraception to be used on a regular basis
and should be kept only for emergency situations, such
as condom breakage.
A study in Thailand assessed the proportion of adoles-
cent mothers aged 19 years or less, regardless of their HIV
status, who were aware of EC [70]. The study was con-
ducted with 104 girls at antenatal or postnatal clinics and
found that close to 85% of the adolescent mothers were
aware of EC, though less than 30% had used it in the past.
The authors summarize that health care providers should
be the sources of information on contraceptive methods
for adolescents.
EC can be achieved either by taking a progestin pill
(1.5 mg of LNG) as soon as possible and not later than
72 hours after unprotected intercourse, or by inserting an
I U Du pt o5d a y sf r o mu n p r o t ected sexual intercourse
(before the possible implantation of a fertilized egg
occurs). According to the 2008 British HIV Association
Guidelines for the management of sexual and reproduc-
tive health of people living with HIV infection, quoting a
statement of the Faculty of Family Planning and Repro-
ductive Health Care, London [10], the dose of hormonal
EC should be doubled in woman who is taking HAART.
A tt h et i m eo ft h i sr e c o m m e n d a t i o nt h e r ew e r en os t u -
dies confirming that this dose increase was required. The
guideline suggests that perhaps the IUD is a more appro-
priate method for EC in woman who is HIV-positive and
on HAART.
Carten et al. reported the results of the first prospective
study assessing the effect of EFV on PK of 0.75 mg LNG,
used as a hormonal EC [71]. EFV reduced the AUC of
LNG significantly (> 50%). The authors confirmed the
recommendations in the British HIV Association Guide-
lines, to increase the hormonal dose though they recog-
nized that the minimum effective LNG concentration is
not known. They also pointed out the importance of dual
methods of contraception.
EC could be an important option of contraception in
HIV-positive girls, who are well trained to use condoms,
and will recognize a problem such as damage for instance.
It has less pill and chemical burden on the body, though
the effectiveness of a standard dose with concomitant
ARV therapy is still unconfirmed.
Conclusion
There are no studies at present assessing the contraceptive
choice in adolescent HIV-positive girls. This is an emer-
ging group of young people with HIV who are showing
similar sexual risk behaviors as their non-HIV infected
peers. The best contraceptive option is the one that works
for the patient. Currently the most effective option for pre-
venting STIs and unintended pregnancy is the dual
method of male condom for STD/HIV prevention and
either HC or IUD for pregnancy prevention. There is an
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bolic outcomes of HC, especially the effect of injectable
progestins on bone metabolism, in adolescent HIV-
positive girls. Health professionals should discuss sexual
risk and contraceptive choices with HIV-positive adoles-
cents as early as possible and preferably before the start of
sexual life. The informed decision should be made by the
adolescent girl based on her lifestyle, sexual activity and
reproductive history.
Perhaps Nong could have been given a different
choice...
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